Hikma Pharmaceuticals buy BNP Paribas
Start price
14.05.25
/
50%
€23.40
Target price
14.05.26
-
Performance (%)
-29.66%
End price
15.05.26
€16.46
Summary
This prediction ended on 15.05.26 with a price of €16.46. The price of Hikma Pharmaceuticals has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.66%. Dividends of €0.41 are taken into consideration when calculating the performance. BNP_Paribas has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Hikma Pharmaceuticals | 2.783% | 2.783% | -30.560% |
| iShares Core DAX® | 0,27 % | 1,80 % | 4,85 % |
| iShares Nasdaq 100 | 1,88 % | 2,15 % | 37,07 % |
| iShares Nikkei 225® | 3,58 % | 5,31 % | 58,40 % |
| iShares S&P 500 | 0,15 % | 1,09 % | 25,28 % |
Comments by BNP_Paribas for this prediction
In the thread Hikma Pharmaceuticals diskutieren
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Ratings data for HKMPF provided by MarketBeat
In the thread Trading Hikma Pharmaceuticals
Die von BNP_Paribas gewählte maximale Laufzeit wurde überschritten